Collegium Pharmaceutical’s CEO to Present at the 26th Annual Piper Jaffray 2014 Healthcare Conference in New York on December 3, 2014
Canton, MA – November 25, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced that the Company’s President and CEO, Michael Heffernan, will present the Company’s corporate overview on Wednesday, December 3, 2014 at 2:50pm EDT at the 26th Annual Piper Jaffray 2014 Healthcare Conference. The conference will be held at The New York Palace in New York City.
The Company’s lead development program is Oxycodone DETERx®, an abuse-deterrent, extended-release oxycodone microsphere-in-capsule product utilizing its proprietary DETERx®technology. The Oxycodone DETERx®formulation was specifically designed to provide and preserve extended-release of the active ingredient following the most common methods of product tampering employed by drug abusers (e.g., crushing, chewing, heating for IV injection, etc.). Following an earlier announced successful Pre-NDA meeting and completion of its Phase 3 study, Collegium remains on track to file the NDA for Oxycodone DETERx® by the end of 2014. The Oxycodone DETERx®program has been designated Fast Track Status by the FDA due to its potential to address the problem of prescription drug abuse, a major public health issue in the U.S.
About DETERx® Technology
The DETERx® drug technology platform consists of a microsphere-in-capsule formulation. While developed primarily to provide abuse-deterrent properties to protect against common methods of tampering such as chewing, crushing, insufflation and extraction for IV injection, the multi-particulate design is expected to enable patients with difficulty swallowing to open the capsule and to administer the contents sprinkled onto food, directly into the mouth, or via a feeding tube, while maintaining the ER properties of the product. The DETERx® technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have narrow therapeutic windows that would benefit from protection against misuse such as breaking, crushing, grinding, or dissolving the product. The formulation platform is covered by U.S. and international patents and patent applications. Oxycodone DETERx® is the first of a number of product candidates using the DETERx® platform.
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx® formulation platform for the treatment of chronic pain. The DETERx®oral drug delivery technology provides ER delivery, unique abuse-deterrent properties, and flexible dose administration options. For more information, visit the Company’s website at www.collegiumpharma.com.